Global drug development services provider Frontage Laboratories has completed the acquisition of Teddy Clinical Research Laboratory (Shanghai) Ltd., a well-established clinical research laboratory in China.
The move is designed to expand Frontage’s laboratory service capabilities and deepen its presence in China and the broader Asia-Pacific clinical research market.
With this acquisition, Frontage aims to support the growing demand for multi-regional clinical trials (MRCTs) and China-based clinical studies.
Expanding Clinical Laboratory Capabilities in China
Teddy Lab has built a strong reputation as a trusted clinical research laboratory in China. Over the years, it has supported more than 1,500 clinical trials across a wide range of therapeutic areas.
The laboratory operates under globally recognized quality systems, including:
• CAP-accredited laboratory standards
• NGSP Level 1 certification
• GCP-compliant clinical operations
• Qualification as a Class II Unsealed Radioactive Material Workplace
These certifications allow the company to deliver regulatory-ready laboratory data for pharmaceutical and biotechnology partners.
Teddy Lab has also supported regulatory inspections and contributed to the successful approval of over 50 new drugs.
Supporting Growing Demand for Multi-Regional Clinical Trials
With the acquisition, Frontage expands its central laboratory footprint in China.
This enhanced infrastructure will help the company address rising demand for:
• Domestic clinical trials within China
• Multi-regional clinical trials (MRCTs)
• Global regulatory submissions
By integrating Teddy Lab’s expertise with its existing platform, Frontage plans to offer a more seamless clinical development experience for global drug developers.
Building a Fully Integrated Drug Development Platform
Frontage already provides a wide range of services across the drug development lifecycle. The addition of Teddy Lab strengthens its integrated service platform, which includes:
• Bioanalytical services
• Drug metabolism and pharmacokinetics (DMPK)
• Safety and toxicology studies
• CMC development
• Clinical trial support services
• Central laboratory operations
Together, these capabilities position Frontage as a one-stop development partner for pharmaceutical and biotech companies.
About Frontage Holdings Corporation
Frontage Laboratories operates as a wholly owned subsidiary of Frontage Holdings Corporation.
Headquartered in the United States, the organization has more than 25 years of experience supporting drug development programs worldwide.
Frontage currently operates 26 global sites and provides services ranging from:
• Drug discovery
• API synthesis
• Preclinical testing
• Formulation development
• GMP manufacturing
• Clinical trial services
The company has played a key role in helping clients secure regulatory approvals across the United States, Canada, Europe, and Asia.
Bottom line:
The acquisition of Teddy Lab strengthens Frontage’s laboratory infrastructure in China, enabling the company to better support global clinical trials and regulatory submissions for pharmaceutical and biotech innovators.